Results 241 to 250 of about 11,332,305 (264)
Some of the next articles are maybe not open access.
Identifying Genetic Risk for Amyloid-Related Imaging Abnormalities
NeurologyIn the last 2 years, there have been 3 successful trials of antiamyloid antibodies in Alzheimer disease (AD): aducanemab, now controversially US Food and Drug Administration-approved under the accelerated approval pathway1; lecanemab, now FDA-approved2; and donanemab, now going through the approval process.3 All 3 share a common broad mechanism, that ...
John, Hardy, Jonathan M, Schott
openaire +2 more sources
Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies
Journal of Alzheimer's Disease, 2018Background: Amyloid-related imaging abnormalities with effusion or edema (ARIA-E) reported in patients with mild-to-moderate Alzheimer’s disease in bapineuzumab phase III studies. Objectives: Assess symptoms, clinical severity, and ARIA-E outcomes, and to evaluate effects on cognition and function.
H Robert, Brashear +5 more
openaire +2 more sources
Neurology
To report a case of fatal super-refractory status epilepticus associated with amyloid-related imaging abnormalities (ARIA).We describe the history, neuroimaging, EEG, and brain pathology findings of a 75-year-old patient with mild cognitive impairment due to Alzheimer disease (homozygous ε4 apolipoprotein status) and a remote history of 3 asymptomatic ...
Joel Neves Briard +3 more
openaire +2 more sources
To report a case of fatal super-refractory status epilepticus associated with amyloid-related imaging abnormalities (ARIA).We describe the history, neuroimaging, EEG, and brain pathology findings of a 75-year-old patient with mild cognitive impairment due to Alzheimer disease (homozygous ε4 apolipoprotein status) and a remote history of 3 asymptomatic ...
Joel Neves Briard +3 more
openaire +2 more sources
Six Recurrent Amyloid-Related Imaging Abnormality Episodes in a Patient Treated With Aducanumab
JAMA Neurology, 2022Jacob N, Hall +6 more
openaire +2 more sources
Molecular Imaging in Oncology: Current Impact and Future Directions
Ca-A Cancer Journal for Clinicians, 2022Martin G. Pomper, Steven P Rowe
exaly
Amyloid-related imaging abnormalities during aducanumab for AD
Reactions Weekly, 2021openaire +1 more source
Amyloid-Related Imaging Abnormalities (ARIA): essential insights for diagnosis and management
Learning objectives: 1. Explain the pathophysiology of ARIA in the context of Alzheimer’s disease and provide a brief overview of monoclonal antibodies used in its treatment. 2.openaire +1 more source

